1. Hu SS. Summary of the Chinese Cardiovascular Health and Disease Report 2020. (Chinese);Chinese Circulation Journal,2021
2. Interpretation of the key points of the "Chinese Cardiovascular Health and Disease Report 2022". (Chinese);Ma;Chinese General Practice,2023
3. Chinese Journal of Cardiovascular Diseases Editorial Committee. Chinese Cardiovascular Disease Prevention Guidelines (2017). (Chinese);Chinese Journal of Cardiology,2018
4. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT2 inhibitors in adult patients with type 2 diabetes: a systematic review;González-González;BMJ Open,2021
5. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes;Thieu;Patient Prefer Adherence,2019